Skip Navigation
Search Menu

 
Print This Page
Share this page: More
 

Search Results

A total of 243 matching records were found.

A085
A Pilot Trial of AVD in addition to Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

A087
Protocol AMC-087: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection

ES1216
S1216 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

G0264
G0264 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

J0656
A Phase I efficacy and safety study of HPV16-specific therapeutic DNA-Vaccinia vaccination in combination with topical imiquimod, in patients with HPV16 high grade cervical dysplasia (CIN2/3)

J08130
Cytokine Expression During Radiation Therapy for Breast Cancer

J0859
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

J0867
Exploration and estimation of intratumoral concentration and activity of lapatinib in vivo in vestibular schwannomas.

J09100
A safety and feasibility trial of boost vaccinations of a lethally irradiated, allogeneic pancreatic tumor cell vaccine transfected with the GM-CSF gene given alone or in combination with either a single intravenous dose or daily metronomic oral doses

J09143
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC T2008-002

J1055
Reduced intensity, partially HLA mismatched allogeneic BMT for hematologic malignancies using donors other than first-degree relatives

J11105
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

J11114
A Multicenter Access and Distribution Protocol for unlicensed cryopreserved Cord Blood Units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications

J11120
A phase II trial of low dose fractionated radiation therapy as a chemo-potentiator of salvage temozolomide for recurrent anaplastic astrocytoma and glioblastoma multiforme

J11143
Multiparametric MRI for assessing radiotherapy treatment response of prostate cancer

J11155
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer

J11157
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate

J11159
A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies (BMT CTN 1101)

J11164
Intra-arterial chemotherapy for the treatment of progressive diffuse intrinsic pontine gliomas (DIPG).

J1137
An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors

J1192
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer

J12102
J12102:An Exploratory Study of the Biologic Effects of Nivolumab and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)

J12106
A Phase II Trial of Reduced Intensity Conditioning and HLA-matched or partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-Risk Solid Tumors

J12114
Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V600-Mutation Positive Solid Tumors

J12121
A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands

J12131
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers (BET115521)

J12133
Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases

J12138
J12138, A Phase II trial to improve outcomes in patients with resected pancreatic adenocarcinoma at high risk for recurrence using epigenetic therapy

J1214
J1214, A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or microsatellite instability phenotype

J1256
Multiple Phase 1 Safety Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies

J1262
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies

J1273
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma

J1281
J1281, A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

J1282
J1282 A Phase I/II Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

J1283
A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma

J1284
Pre-operative Paravertebral Blocks to Decrease Post-operative Pain Following Mastectomy with Immediate Tissue Expander Reconstruction

J1299
A pilot study investigating antitumorigenic potential of topical itraconazole in the treatment of basal cell carcinoma

J1304
Presenting Patient-Reported Outcomes Data to Improve Patient and Clinician Understanding and Use

J13101
J13101 "A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors".

J13104
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)

J13105
Early Detection of Pancreatic Cystic Neoplasms

J13119
J13119; A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

J13128
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS

J13134
A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of HLA-matched, Partially HLA-mismatched, HLA-haploidentical or matched unrelated Bone Marrow for Patients with Refractory Systemic Lupus Erythematosus

J13138
J13138; A Pilot Study of SGI-110 in Combination with an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

J13146
J13146: An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects with Metastatic Pancreatic Adenocarcinoma

J13161
A Pediatric Blood and Marrow Transplant Consortium (PBMTC) multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T cell replete Bone Marrow with post-transplantation cyclophosphamide for Children and Young Adults with Hematologic Malignancies

J1322
Combination of External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma and Patients with Solid Tumors Metastatic to Bone

J1326
(MC1114) A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian tube Cancers

J1331
Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1-infected individuals

J1343
A Randomized Phase II Study of Autologous Stem Cell Transplantation with tadalafil and lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma with Nivolumab and Lenalidomide +/- MILs in the Relapse Setting

J1345
Quantitative MRSI to Predict Early Response to Belinostat Therapy in Newly-Diagnosed Glioblastomas

J1349
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

J1353
A Randomized Phase II Study of Epigenetic Therapy with Azacitidine and Entinostat with Concurrent Nivolumab versus Nivolumab Alone in Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer.

J1354
Rituximab and brentuximab vedotin with deferred BMT for relapsed classical Hodgkin lymphoma

J1357
A Pilot Study of Allopurinol as a Modifier of 6-MP Metabolism in Pediatric ALL

J1365
Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors

J1366
Role of Human Papillomavirus in Head and Neck Squamous Cell Cancer

J1367
A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

J1369
J1369, A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

J1380
A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

J1394
Cancer of the Pancreas Screening-5 A multi-center clinical trial

J1403
Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma

J1409
Immune Evaluation Study of Sipuleucel-T in African American and non-African American Men with Castrate Resistant Prostate Cancer (Karmanos Cancer Institute protocol # 2013-108)

J14106
Non-invasive Detection of Cancer DNA in Blood and Urine

J1412
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

J14126
J14126, A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma

J14127
J14127: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

J1414
Neoadjuvant Nivolumab, or Nivolumab in combination with Ipilimumab, in Resectable Non-Small-Cell Lung Cancer

J14144
J14144-Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced/Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma

J14146
A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)

J1415
A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients with Stage IV (including Pleural Effusion) Non-Squamous Non-Small Cell Lung Cancer (NSCLC) who have Failed Two Lines of Anti-Cancer Therapy.

J1416
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies RE-sensitizing with Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

J14161
Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in combination with Cisplatin and Irinotecan in Subjects with Metastatic Pancreatic Cancer

J14164
20140106 (formerly CFZ008): Phase 1bStudy of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

J14166
Prospective evaluation of high-dose (8 g/m2) systemic methotrexate in patients with breast cancer and leptomeningeal metastasis

J14168
A Safety Study of Fingolimod with Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

J14174
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment (Protocol No.: TO-TAS-102-107)

J14177
A Phase I Study of Mobilization and Treatment of Disseminated Tumor Cells in Men with Metastatic Prostate Cancer

J14179
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m² IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m² SC/IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m² SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent

J14182
J14182 - A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC).

J14191
A Feasibility Study of the VibrentTM Smartphone App for Head & Neck Cancer Patients: Supporting Pain Management of Radiation-Induced Mucositis

J1424
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients with Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

J1426
“A Randomized Phase II Study of Subventricular Zone (SVZ) Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme”

J1428
A randomized multicenter pivotal study of CDX-011 (CR011-vcMMAE) in patients with metastatic, GPNMB over-expressing, triple-negative breast cancer

J1429
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults with NF1- Associated Morbid Plexiform Neurofibromas

J1432
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

J1435
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery (UWI2013-01-02)

J1439
“A Pilot Study Using Amide Proton Transfer (APT) Magnetic Resonance Imaging to Distinguish Tumor Bearing Cancerous Tissue from Normal Tissue in Patients with Glioma”

J1441
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer

J1444
The feasibility and biologic effect of a modified Atkins-based intermittent fasting diet in patients with high-grade astrocytoma

J1454
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA)

J1480
My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents (Protocol Number: ML28897/PRO 02)

J1489
A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

J1494
A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

J1498
A Phase I Study of Intravaginally Administered Artesunate In Women with High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

J1504
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance (DCP Protocol #: UAZ2014-03-01)

J15106
A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

J15117
J15117 - Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors

J15119
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7–Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)

J15122
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer (Protocol Number: GS-US-350-1604)

J15132
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (MYSTIC)

J15134
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection ( Protocol Number: WO29636)

J15138
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

J15145
Study of 18F-DCFPyL PET/CT in the Assessment of Patients with Renal Cell Carcinoma

J15155
An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Subjects With Non-Small Cell Lung Cancer

J15165
Phase II study of shortened-duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high-dose posttransplantation cyclophosphamide in malignancies that are challenging to engraft

J15180
Phase II Randomized Observation versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) Trial

J15183
A Phase II Trial of Reirradiation Combined with Open Label MK-3475 (Pembrolizumab) in Patients with Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)

J15184
J15184 - A phase Ib, open-label, dose-escalation study of the safety and pharmacology of GDC-0919 administered with Atezolizumab in patients with locally advanced or metastatic solid tumors

J15188
EMBARK: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy (Protocol Number: MDV3100-13)

J15202
J15202 - Phase I/Ib, single-arm, open-label, multi-center trial using ARQ-761 (beta-lapachone) treatment with gemcitabine/nab-paclitaxel chemotherapy in metastatic, unresectable, or recurrent pancreatic cancer

J15203
Pilot Biomarker Study of Stereotactic Body Radiation Therapy for Prostate Cancer Oligometastases

J15214
A Pilot Study of Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine

J15215
J15215-Phase I study of neo-adjuvant RO7009789 alone or neo-adjuvant RO7009789 plus nab-paclitaxel and gemcitabine followed by adjuvant RO7009789 plus nab-paclitaxel and gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma.

J15216
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men with Prostate Cancer

J1522
A Randomized Phase 2 Study of Sipuleucel-T with or without Radium-223 in Men with Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer

J15220
Study of Immunotherapy in Newly Diagnosed Glioblastoma: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

J15221
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (NCI# 9844)

J15222
J15222: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

J15224
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS) (Study Number: MIP-1404-3301)

J15230
A Phase 1a/b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

J15231
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

J15235
(14T-MC-JVDJ) An Open-Label, Multicenter, Phase 1 Study of Ramucriumab Plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

J15237
A Phase II Study of GM-CSF secreting allogeneic pancreatic cancer vaccine in combination with PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Locally Advanced Adenocarcinoma of the Pancreas

J15239
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer (Hoosier Cancer Research Network GU14-182)

J1525
A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma.

J1538
J1538: A study of using epigenetic modulators to enhance response to MK-3475 in microsatellite stable advanced colorectal cancer

J1541
Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies (Protocol CPDR001X2101)

J1542
A Randomized Phase 2 Trial of Axitinib and TRC105 versus Axitinib Alone (Including A Lead in Phase 1b Dose-Escalation Portion) In Patients with Advanced or Metastatic Renal Cell Carcinoma (Protocol number: 105RC101)

J1547
GEMTUZUMAB OZOGAMICIN (MYLOTARG) EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS IN THE UNITED STATES WITH RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA WHO MAY BENEFIT FROM TREATMENT AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY

J1548
A Pilot Study of Dexamethasone Therapy Prior to Rechallenge with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer Dex EXTends Enza Response (The DEXTER Trial)

J1551
Phase 1-2 Study of MEDI4736 Alone or in Combination with ADXS11-001 in Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer

J1557
Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-ß receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study

J1564
“The IDEA Study (Individualized Decisions for Endocrine therapy Alone): A prospective, single-arm cohort study of patients receiving endocrine therapy alone (without radiotherapy) after breast conserving surgery for early-stage, post-menopausal breast cancer patients whose tumors have favorable biologic features”

J1566
T2014-001 A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

J1568
J1568-A Randomized Study of a GM-CSF secreting allogeneic pancreatic cancer vaccine with or without a PD-1 Blockade Antibody (Nivolumab) for the Neoadjuvant and Adjuvant Treatment of Patients with Surgically Resectable Adenocarcinoma of the Pancreas

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

J1603
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell Carcinoma (Protocol Number: IUSCC-0551)

J1604
An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY) (Study Code D2615C00001)

J1607
A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-programmed Death-1 Monoclonal Antibody, in Patients with B-cell Malignancies

J1609
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumorO-6-methylguanine DNA methyltransferase) Glioblastoma

J16107
Partnering Around Cancer Clinical Trials (PACCT)

J16108
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

J16119
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY) (Study Number: PyL 2301)

J16121
Improving Outcomes for Younger Breast Cancer Survivors: A Phase III Randomized Trial Targeting Behavioral Symptoms in Younger Breast Cancer Survivors. The Pathways to Wellness (PTW) Study

J16126
ADXS001-02: Phase 3 Study Of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment For High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence

J16131
A Phase 1b Study of Enzalutamide plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC) (Sponsor Protocol c15-160)

J16138
Phase I Safety Study of Stereotactic Radiosurgery with Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects with Recurrent or Advanced Chordoma

J1615
A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors (Sponsor Protocol Number: D419NC00001)

J16163
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

J1618
A phase II study of definitive therapy for newly diagnosed men with oligometastatic prostate cancer

J1621
9825 A Phase 2 Study of olaparib and cediranib for the treatment of recurrent ovarian cancer

J1630
Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study (Protocol number: GCP-10100)

J1640
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism

J1643
A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

J1645
Open-label, Multicenter Phase 1/2 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors (Protocol Number: 0761-014)

J1646
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma (Protocol Number: TC-UT-03-P)

J1649
A Nerve Sheath Tumor Bank from Patients with NF1

J1651
Phase 2 Study of Azacitidine in Combination with Pembrolizumab in Relapsed/ Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older ( equal to 65 Years) AML Patients

J1652
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155).

J1653
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta®) versus Sunitinib (Sutent®) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma (Protocol Number: B9991003)

J1667
J1667 - A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors

J1672
A phase 2-3, multicenter, Randomized, Double-Blind Study of selinexor (KPT-330) versus placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

J1674
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors (SCRX001-006)

J1677
J1677- A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

J1682
Randomized Phase II Study of Neoadjuvant Nivolumab with and without Urelumab in Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder

J1688
Regenerative Medicine to Restore Normal Hematopoiesis in Aplastic Anemia

J1689
A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations (Protocol No.: PRN1371-001)

J1690
9875 Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

J1692
A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects with Muscle-Invasive Transitional Cell Carcinoma of the Bladder (Protocol TAR-200-101)

J1693
Neoadjuvant Enoblituzumab (MGA271) in Men with Localized Intermediate and High-Risk Prostate Cancer – a Pilot and Biomarker Study

J1696
J1696 - A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study Of The Efficacy And Safety Of Trastuzumab Emtansine In Combination With Atezolizumab Or Atezolizumab-Placebo In Patients With Her2-Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab And Taxane Based Therapy

J1717
Expansion of naïve donor immune cells reactive to tumor neoantigens

N1202
Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma

N1301
Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients

N1403
The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide

NCTNA011104
A011104 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

NCTNA011202
A011202 A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

NCTNA011401
A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

NCTNA021501
A021501 Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

NCTNA051301
A051301 A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-Cell lymphoma of the activated B-Cell subtype

NCTNA0577
N0577 CODEL: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

NCTNA071401
A071401 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

NCTNA081105
A081105 Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

NCTNA091404
A091404 A Phase II Study of Enzalutamide for Patients with Androgen Receptor Positive Salivary Cancers

NCTNA151216
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

NCTNA221405
A221405 A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

NCTNB51
B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

NCTNB55
B55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (D081CC00006)

NCTNE1910
E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

NCTNE1Z11
E1Z11 A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NCTNE2112
E2112 A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer

NCTNE3311
E3311 Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

NCTNE4412
E4412 A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

NCTNE4512
E4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCTNEA1131
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy versus Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

NCTNEA5142
EA5142 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

NCTNEAY131
EAY131 Molecular Analysis for Therapy Choice (MATCH)

NCTNG0286B
G0286B A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

NCTNGY004
GY004 A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

NCTNGY005
GY005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

NCTNGY007
GY007 A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCTNMDS
NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Natural History Study

NCTNNBR003
BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

NCTNNCC003
CC003 Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

NCTNR1112
R1112 Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

NCTNS1011
S1011 A Phase III Surgical Trial to Evaluate The Benefit Of A Standard Versus An Extended Pelvic Lymphadenectomy Performed At Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer

NCTNS1207
S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu-Negative Breast Cancer

NCTNS1314
S1314 A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

NCTNS1400
S1400 A Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

NCTNS1418
S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than / equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

NCTNS1500
S1500 A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET)

PAALL05B1
A Children?s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

PAALL0932
AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

PAALL1131
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

PAALL1231
AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

PAALL1331
AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

PAAML1031
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.

PAAML1331
AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

PACCL0922
A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

PACNS02B3
ACNS02B3 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

PACNS0332
ACNS0332 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

PACNS0821
Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

PACNS0831
ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

PACNS1123
ACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

PACNS1221
ACNS1221 A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age

PAHOD04B1
Hodgkin Disease (HD) Banking Study

PANBL1221
ANBL1221, A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

PANHL04B1
Rare and Cutaneous Non-Hodgkin Lymphoma Registry

PANHL1131
ANHL1131, Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients.

PANHL12P1
A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

PAREN03B2
AREN03B2 Renal Tumors Classification, Biology, and Banking Study

PARST1321
ARST1321 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

PASCT1221
A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)

PIACCL1333
ACCL1333/CV185155: A Phase III Randomized, Open Label, Multi-center Study on the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase

R0926
R0926 A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

TBCRC026
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer

TBCRC030
A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker (TBCRC 030)

TBCRC031
A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (“AC”) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations – The INFORM BRCA 1/2 Study: Investigation of Neoadjuvant Chemotherapy for Mutation Carriers: BRCA1/2 (TBCRC 031)

TBCRC034
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy (TBCRC 034)

Z15111
Exploratory Study of the CytoRADx System as a Biodosimeter

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

 

NCI CCC